Abstract
Recently, the inhibitor dipeptidyl peptidase-4 has been reported to be beneficial in the treatment of type 1 diabetes mellitus. For the first time, this study evaluates the effect of vildagliptin on β -cell neogenesis and lipid homeostasis in a later phase of type 1 diabetes. In Fischer rats, diabetes was induced with alloxan. After confirmation of diabetic status, the animals received no treatment for 30 days to establish a late phase of the disease these animals. After this period, the animals were treated with vildagliptin via gavage for 30 consecutive days. Fasting blood glucose, serum insulin, lipid profile and pancreatic histology were evaluated. Treatment with vildagliptin increased serum levels of insulin, improved beta cell function and improved the lipid profile. Histological analyses revealed that this treatment increased the populations of pancreatic β-cells in the diabetic animals. The treatment was effective in improving the mass and function of β-cells and contributed to lipid homeostasis, in an experimental model of type 1 diabetes.
Keywords: β-cells, DPP4 inhibitor, lipid profile, neogenesis, type 1 diabetes, vildagliptin.
Current Pharmaceutical Biotechnology
Title:Vildagliptin Induces β-Cell Neogenesis and Improves the Lipid Profile in a Later Phase of Type 1 Diabetes
Volume: 16 Issue: 1
Author(s): Pedro H. de Amorim Miranda, Otavio M. Monteiro, Joamyr V. Rossoni, Marcelo E. Silva, Wanderson G. de Lima and Daniela C. Costa
Affiliation:
Keywords: β-cells, DPP4 inhibitor, lipid profile, neogenesis, type 1 diabetes, vildagliptin.
Abstract: Recently, the inhibitor dipeptidyl peptidase-4 has been reported to be beneficial in the treatment of type 1 diabetes mellitus. For the first time, this study evaluates the effect of vildagliptin on β -cell neogenesis and lipid homeostasis in a later phase of type 1 diabetes. In Fischer rats, diabetes was induced with alloxan. After confirmation of diabetic status, the animals received no treatment for 30 days to establish a late phase of the disease these animals. After this period, the animals were treated with vildagliptin via gavage for 30 consecutive days. Fasting blood glucose, serum insulin, lipid profile and pancreatic histology were evaluated. Treatment with vildagliptin increased serum levels of insulin, improved beta cell function and improved the lipid profile. Histological analyses revealed that this treatment increased the populations of pancreatic β-cells in the diabetic animals. The treatment was effective in improving the mass and function of β-cells and contributed to lipid homeostasis, in an experimental model of type 1 diabetes.
Export Options
About this article
Cite this article as:
de Amorim Miranda H. Pedro, Monteiro M. Otavio, Rossoni V. Joamyr, Silva E. Marcelo, de Lima G. Wanderson and Costa C. Daniela, Vildagliptin Induces β-Cell Neogenesis and Improves the Lipid Profile in a Later Phase of Type 1 Diabetes, Current Pharmaceutical Biotechnology 2015; 16 (1) . https://dx.doi.org/10.2174/1389201015666141113124341
DOI https://dx.doi.org/10.2174/1389201015666141113124341 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Continuous Glucose Monitoring: Is it Helpful in Pregnancy?
Current Diabetes Reviews Local Drug Delivery Based Treatment Approaches for Effective Management of Periodontitis
Current Drug Therapy Natural Alkaloids and Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Effective Management of the Type 2 Diabetes Patient with Cardiovascular and Renal Disease: Secondary Prevention Strategies after a Myocardial Infarction
Current Diabetes Reviews <i>Nigella sativa</i>, as Preventive Strategy in COVID-19
Current Traditional Medicine Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Variability in the Response to Non-pharmacological Treatments in Patients with Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Hypertension and Angiogenesis
Current Pharmaceutical Design Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Current Vascular Pharmacology Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery One-pot Synthesis and its Practical Application in Pharmaceutical Industry
Current Organic Synthesis Exploring the Cardio-metabolic Relevance of T-cadherin: A Pleiotropic Adiponectin Receptor
Endocrine, Metabolic & Immune Disorders - Drug Targets Prevention of Endothelial Dysfunction and Cardiovascular Disease by n-3 Fatty Acids-Inhibiting Action on Oxidative Stress and Inflammation
Current Pharmaceutical Design Sex Steroids Effects in Normal Endocrine Pancreatic Function and Diabetes
Current Topics in Medicinal Chemistry Oxidative Stress, Inflammation and Endothelial Biomarkers in Arterial Hypertension
Current Hypertension Reviews Editorial (Thematic Issue: AMPK: New Frontiers in Human Diseases)
Current Drug Targets Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety The Role of Platelets in Athero-Thrombotic Events
Current Pharmaceutical Design Role of the Autonomic Nervous System in the Endothelial Dysfunction of the Metabolic Syndrome
Current Hypertension Reviews Dyslipidaemia Related to Insulin Resistance and Cardiovascular Disease in South Asian and West African Populations
Current Pharmaceutical Design